KI2011 is a novel potent FLT3 tyrosine kinase inhibitor in acute myeloid leukemia cells with FLT3-mutation

被引：0
|
作者：
Ryu, Hwani [1 ]
Song, Jie-Young [1 ]
Ahn, Jiyeon [1 ]
机构：
[1] Korea Inst Radiol & Med Sci, Seoul, South Korea
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-806
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
806
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
    Stone, RM
    DeAngelo, DJ
    Klimek, V
    Galinsky, I
    Estey, E
    Nimer, SD
    Grandin, W
    Lebwohl, D
    Wang, YF
    Cohen, P
    Fox, EA
    Neuberg, D
    Clark, J
    Gilliland, DG
    Griffin, JD
    BLOOD, 2005, 105 (01) : 54 - 60
  • [2] Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition
    Zhu, Ruiqi
    Shirley, Courtney M.
    Chu, S. Haihua
    Li, Li
    Nguyen, Bao H.
    Seo, Jaesung
    Wu, Min
    Seale, Tessa
    Duffield, Amy S.
    Staudt, Louis M.
    Levis, Mark
    Hu, Yu
    Small, Donald
    LEUKEMIA, 2024, 38 (07) : 1581 - 1591
  • [3] Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition
    Zhu, Ruiqi
    Shirley, Courtney
    Chu, Haihua
    Li, Li
    Bao Nguyen
    Seo, Jaesung
    Seale, Tessa
    Duffield, Amy
    Staudt, Louis M.
    Levis, Mark J.
    Hu, Yu
    Small, Donald
    BLOOD, 2023, 142
  • [4] A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
    Levis, M
    Tse, KF
    Smith, BD
    Garrett, E
    Small, D
    BLOOD, 2001, 98 (03) : 885 - 887
  • [5] Antitumor triazoloacridinone C-1305 as a potent FLT3 tyrosine kinase inhibitor in human acute myeloid leukemia (AML) cells
    Augustin, E.
    Skwarska, A.
    Koprowska, J.
    Pelikant, I.
    Konopa, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 113 - 113
  • [6] Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
    Juanjuan Zhao
    Yongping Song
    Delong Liu
    Biomarker Research, 7
  • [7] Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
    Alvarado, Yesid
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    Ravandi, Farhad
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Estrov, Zeev
    Andreeff, Michael
    Cortes, Jorge E.
    CANCER, 2014, 120 (14) : 2142 - 2149
  • [8] Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation
    Carlos Best-Aguilera
    O. Rodrigo Gómez-Vázquez
    A. Elizabeth Guzmán-Hernández
    R. Monserrat Rojas-Sotelo
    Current Oncology Reports, 2017, 19
  • [9] TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia
    Wall, Hayley S.
    Bao Nguyen
    Li, Li
    Greenblatt, Sarah M.
    Brown, Patrick
    Levis, Mark J.
    Small, Donald
    BLOOD, 2012, 120 (21)
  • [10] NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience
    Curti, Antonio
    Rambaldi, Alessandro
    Cattaneo, Chiara
    Cairoli, Roberto
    Della Porta, Matteo
    Chiusolo, Patrizia
    Lussana, Federico
    Ubezio, Marta
    Mancini, Valentina
    Cano, Isabel
    Besliu, Carmen
    Claussen, Christian Hove
    Gatto, Rosalinda
    Crivori, Patrizia
    Colajori, Elena
    Somaschini, Alessio
    Davite, Cristina
    Isacchi, Antonella
    Ardini, Elena
    Mahnke, Lisa
    Montesinos, Pau
    CANCER RESEARCH, 2023, 83 (08)
12345